INDEPENDENT ANTI-DOPING REFERENCE2026 · CHECKED 08 NOV 2027 PUBLISHED ↗
WADAFUK!?
A REBELLIOUS NAME. A CAREFUL REFERENCE.

SHOW YOUR
WORK.

Trust comes from sources, visible limits, and corrections.

Independent, by design.

WADAFUK!? is an independent educational project. We are not WADA, an anti-doping organization, or a medical service. We do not certify products, issue TUEs, or provide individual medication clearance.

The visual identity is intentionally irreverent. Regulatory statements should always be traceable to official documents. Where an official rule and this summary differ, use the official rule and consult the relevant authority.

COVERAGE / HONESTLY

A foundation. Not a finished encyclopedia.

14Top-level category entry points
280Public substance / method profiles
198Source-checked selected-source summaries
76Source-checked regulatory-only summaries

274 source-checked educational profiles and 6 seed profiles. These counts describe the current public catalog, not the private research drafts. Source checking is not independent clinical signoff or an individual anti-doping determination. Independent review remains pending.

Category entry points are navigation aids, not a measure of complete WADA coverage. Subcategories, named examples, class clauses, historical rules and scientific reviews are incomplete. Selected-source summaries are not systematic reviews. A universal percentage for “all banned substances” would be misleading because open-ended classes cover unnamed substances.

No exact match means unresolved. It never means “safe” or “permitted.” Monitoring is stored separately from prohibition.

Four kinds of statements.

01

Official regulatory fact

An edition, section and direct official source. Applies within that source’s scope and dates.

02

Scientific finding

A cited study or authoritative label, with population, outcome and limitations. Mechanism alone is not proof of benefit.

03

Editorial interpretation

Our explanation of what the evidence means. Identified separately from the regulation and the underlying findings.

04

Open question

Unreviewed, incomplete, ambiguous or disputed material. Kept visible rather than filled with a confident guess.

A year is not a source version.

The 2027 List is published for 1 January 2027. Its currently linked clean PDF is the 4 November 2026 revision. The production model therefore tracks both effective dates and document revisions, with content hashes when authorized local copies are obtained.

Source-check dates belong to individual records and are shown on each profile. The current public catalog contains:

These are recorded checks, not live regulatory verification. Independent regulatory review remains pending; medical summaries also need specialist review. Publication does not provide athlete or medication clearance.

  1. Official regulationWADA · 2026 Prohibited List↗
  2. Forthcoming regulationWADA · 2027 List · 4 November revision↗
  3. Official explanationWADA · 2027 modifications↗

Rights-aware research.

Public availability is not an open-data license. WADA restricts unauthorized automated extraction and republication. Global DRO restricts automated use and redistribution. No scraper, mirrored medication database or live Global DRO integration is running.

The prototype uses short original summaries and direct references. Source-use permission and legal review for the intended scale of normalization and public display remain ongoing publication priorities.

  1. Reuse termsWADA · Legal notice↗
  2. Scope and reuse termsGlobal DRO · Scope and terms↗

Found a problem?

Prepare a correction with the exact claim and supporting evidence. This prototype can create a draft for you; a submission inbox and review workflow are not connected yet.

Prototype: creates a local draft only. A reviewed submission service is planned; no data is sent.

What comes next.

Expand rule-framework validation; obtain independent regulatory and specialist clinical review; develop the correction submission service; continue accessibility and safety-critical search testing; and review source-use permissions for ongoing publication.

Explore the original visual system ↗